本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"）为扩大信息披露的覆 盖面，进一步做好投资者关系管理工作，即日起增加《中国证券报》《上海证券 报》为指定信息披露媒体。增加后公司指定信息披露媒体为《中国证券报》《上 海证券报》《证券时报》和巨潮资讯网（http://www.cninfo.com.cn）。 公司所有公开披露的信息均以在《中国证券报》《上海证券报》《证券时报》 和巨潮资讯网（http://www.cninfo.com.cn）上刊登的正式公告为准，敬请广大投 资者理性投资，注意投资风险。 证券代码：000881 证券简称：中广核技 公告编号：2025-009 中广核核技术发展股份有限公司 关于增加指定信息披露媒体的公告 中广核核技术发展股份有限公司 董事会 2025 年 2 月 19 日 特此公告。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开的日期、时间： 证券代码：000881 证券简称：中广核技 公告编号：2025-008 中广核核技术发展股份有限公司 2025 年第一次临时股东会决议公告 （1）现场会议召开日期、时间：2025年2月14日（星期五）下午3:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2025年2月14日上午9:15至9:25、9:30至11:30、下午1:00至3:00；通过深 圳证券交易所互联网投票系统投票的具体时间为2025年2月14日上午9:15至下午 3:00期间的任意时间。 2.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 3.现场会议召开地点：深圳市福田区深南大道 2002 号中广核大厦北楼 19 层 881 会议室。 4.召集人：公司董事会。 5.主持人：公司半数以上董事推举董事、总经理盛国福先生主持本 ...

为出具本法律意见书之目的，本所委派律师（以下简称"本所律师"）列席了贵 公司本次股东会，并根据有关中国法律、法规的规定及要求，按照律师行业公认的 深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 2803-04 室 邮编：518048 电话：(86-755) 2939-5288 传真：(86-755) 2939-5289 junhesz@junhe.com 北京市君合（深圳）律师事务所 关于中广核核技术发展股份有限公司 2025 年第一次临时股东会的法律意见书 致：中广核核技术发展股份有限公司 北京市君合（深圳）律师事务所（以下简称"本所"）受中广核核技术发展股份 有限公司（以下简称"贵公司"或"公司"）的委托，就贵公司 2025 年第一次临时股东 会（以下简称"本次股东会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》、《上市公司股东大会规则》（以下 简称"《股东大会规则》"）等中国现行法律、法规和规范性文件（以下简称"中国法 律、法规"，为本法律意见书之目的，中华人民共和国（以下简称"中国"，包括香 港特别行政区、澳门特别行政区和台湾省，为出具本 ...

Investment Rating - The report initiates coverage with a "Buy" rating for CGN Technology (000881.SZ) [12] Core Views - CGN Technology is recognized as the leading enterprise in non-power nuclear technology applications in China, part of the China General Nuclear Power Group's "6+1" industrial system [3][19] - The company is currently facing short-term pressure on its performance due to underwhelming new materials business and losses in its cultivation period businesses [22] - The nuclear technology application industry in China has significant growth potential, with the market expected to expand substantially in the coming years [27][28] Summary by Sections Company Overview - CGN Technology is the first stock in non-power nuclear technology and serves as a development platform for non-power nuclear technology applications in China [3][19] - The company focuses on high-performance modified engineering plastics and is a major supplier in various sectors including industrial electrical, automotive, and electronic industries [20] Financial Performance - In 2021, the company achieved a revenue of 79.99 billion yuan, with a year-on-year growth of 20.25%. However, revenues declined by 13.18% and 8.53% in 2022 and 2023 respectively, with a slight recovery in 2024 [22] - The company's net profit for 2023 and the first three quarters of 2024 is projected to be negative due to high costs and competitive pressures [22] New Materials Transition - CGN Technology is optimizing its new materials structure and transitioning towards high-end materials, with traditional product sales expected to grow by approximately 5.5% in the first half of 2024 [4] - The company has seen a significant increase in sales in the "three new" markets, with a year-on-year growth of about 51.8% [4] Accelerator Technology - CGN Technology is a leader in the electronic accelerator market, with a focus on high-energy applications. The company has introduced advanced proton therapy technology and is establishing a production base for proton therapy equipment [5][53] - The market for proton therapy systems in China is projected to be substantial, with a total market size estimated at around 30.7 billion yuan during the 14th Five-Year Plan period [5] Profitability Forecast - The company forecasts a net profit of -3.13 billion yuan in 2024, with a gradual recovery to 1.20 billion yuan in 2025 and 1.90 billion yuan in 2026 [12] - The expected earnings per share (EPS) for 2024, 2025, and 2026 are projected to be -0.33, 0.13, and 0.20 yuan respectively [12]

Financial Performance - The company expects a net loss of between 29 million yuan and 42 million yuan for the year 2024, compared to a net loss of 73.72 million yuan in the same period last year[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 45 million yuan and 64 million yuan, down from a loss of 96.06 million yuan in the previous year[2]. - The basic earnings per share are expected to be a loss between 0.3067 yuan and 0.4442 yuan, compared to a loss of 0.7797 yuan per share last year[2]. Strategic Focus - The company is focusing on its "A+" strategy, with steady progress in operational management, innovation, and reform efforts, particularly in the accelerator and healthcare sectors[4]. - Significant investments are being made in the development and promotion of healthcare, nuclear environmental protection, and silicon photonics businesses, which are currently incurring losses[4]. Market Conditions - The company is experiencing pressure on product prices and gross margins due to industry cycle adjustments and intensified market competition in the new materials business[4]. Asset Management - The company plans to conduct comprehensive asset inspections and impairment tests, with provisions for potential asset impairments[5]. - The preliminary financial data is subject to change, and the final figures will be disclosed in the 2024 annual report[6].

Group 1 - The company 中广核俊尔 (Zhongguang Nuclear Juner) has recently been established with a registered capital of 41.5 million yuan [2] - The legal representative of 中广核俊尔 is 相军 (Xiang Jun) [2] - The business scope of 中广核俊尔 includes manufacturing leather products, plastic products, machinery equipment leasing, import and export of goods, and technology import and export [2] Group 2 - 中广核技 (China General Nuclear Power Corporation) holds 100% ownership of 中广核俊尔 [1]

何祖元先生在任职期间恪尽职守、勤勉尽责，公司及董事会对其在任董事期 间为公司发展做出的贡献表示衷心地感谢。 中广核核技术发展股份有限公司（以下简称"公司"）董事会于 2024 年 12 月 26 日收到非独立董事何祖元先生提交的书面辞职报告，何祖元先生因到龄退 休，申请辞去公司董事及董事会战略委员会委员、董事会薪酬委员会委员职务， 辞职后不再担任公司任何职务。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》和《公司章程》的有关规定，何祖元先生的辞职 不会导致公司董事会成员低于法定最低人数，不影响董事会的正常运作。何祖元 先生的辞职报告自送达公司董事会之日起生效。公司董事会将按法定程序尽快完 成董事的补选工作。截至本公告披露日，其未持有本公司股份。 证券代码：000881 证券简称：中广核技 公告编号：2024-074 特此公告。 中广核核技术发展股份有限公司 关于董事辞职的公告 中广核核技术发展股份有限公司 董事会 2024年12月28日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 ...